Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

PSNC extends deadline for pharmacy teams to take part in 2022 Advice Audit

To allow more community pharmacies to participate in the 2022 Pharmacy Advice Audit, the Pharmaceutical Services Negotiating Committee (PSNC) has extended the participation period by three weeks.

The new deadline stands at March 11 (Friday).


Considering an encouraging submission rate so far of 2,000 pharmacies, the negotiator is aiming to double this figure over the next few weeks to ensure that the audit results have greater impact.

The PSNC stated that greater participation of pharmacy teams will provide critical evidence for its use in funding discussions with government and the NHS, as well as helping build support for the sector through charities, politicians and the national press.

Thanking pharmacy teams who have already taken part in the audit, Mike Dent, PSNC director of Pharmacy Funding, said: “We do now need to hear from many more pharmacies to give our data as much power as we can.

“The results of previous audits have been incredibly valuable in negotiations and wider discussions, and this has never been more important as we push for government to fund pharmacies for the support they give to ‘walk-in’ patients."

He added that the response rates for the earlier two audits were phenomenal, and “we hope to hear from many more of you over this newly extended audit period.”

More For You

NHS app to boost clinical trials

The focus is on encouraging people from underrepresented groups, including minorities from African and Asian heritage, to sign up for clinical trials.

iStock

Government to use NHS app to boost clinical trials

The government’s 10-Year Health Plan is expected to provide a fillip to clinical trials, and it plans to make use of the NHS App to encourage people to sign up as participants.

People will be able to sign up for the NIHR Be Part of Research service (bepartofresearch.uk) on the NHS App for the trials best suited to their interests and needs.

Keep ReadingShow less
US pharma bets big on China to snap up potential blockbuster drugs

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies

US pharma bets big on China to snap up potential blockbuster drugs

US drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters.

Keep ReadingShow less
Alliance Healthcare team raises thousands with charity bike ride to Paris

The Alliance Healthcare team

Alliance Healthcare team raises thousands with charity bike ride to Paris

Eight Alliance Healthcare team members raised over £55,000 for Theodora Children’s Charity by cycling from Surrey to Paris.

From June 13th-15th, the team took on the gruelling 300 mile cross-border Tour D’Alliance 2025 challenge and raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

Keep ReadingShow less
Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less